Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Phathom Pharmaceuticals (PHAT) Accumulated Depreciation & Amortization (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Accumulated Depreciation & Amortization for 4 consecutive years, with $600000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 25.0% to $600000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $600000.0, a 25.0% decrease, with the full-year FY2025 number at $600000.0, down 25.0% from a year prior.
  • Accumulated Depreciation & Amortization was $600000.0 for Q4 2025 at Phathom Pharmaceuticals, down from $800000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $980000.0 in Q1 2022 to a low of $100000.0 in Q1 2023.
  • A 4-year average of $470909.1 and a median of $600000.0 in 2022 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: plummeted 89.8% in 2023, then skyrocketed 100.0% in 2024.
  • Phathom Pharmaceuticals' Accumulated Depreciation & Amortization stood at $600000.0 in 2022, then changed by 0.0% to $600000.0 in 2023, then skyrocketed by 33.33% to $800000.0 in 2024, then dropped by 25.0% to $600000.0 in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Accumulated Depreciation & Amortization are $600000.0 (Q4 2025), $800000.0 (Q4 2024), and $600000.0 (Q3 2024).